Agilent Technologies announces 50,000th shipment of its industry-leading liquid chromatography system

Agilent Technologies Inc. (NYSE: A) today announced it has shipped more than 50,000 Agilent 1100 Series liquid chromatography (LC) systems. Since its introduction in 1995, the Agilent 1100 Series has become the industry’s best-selling LC system, with thousands of customers in a wide range of fields, including pharmaceutical, biotechnology, chemical, petrochemical, foods, forensics and environmental.

“With the largest installed user base ever, the Agilent 1100 Series has become an industry standard for LC and LC/MS applications,” said Karlheinz Bruederle, vice president and general manager of Agilent’s Pharmaceutical Solutions. “Its success is based on a unique combination of performance, reliability and flexibility. The combination continues to earn the respect and trust of new customers, particularly in growing fields such as proteomics and drug compound purification. We appreciate the commitment of our customers and look forward to continuing the evolution of the 1100 Series platform.”

Invented more than a century ago, liquid chromatography is a method of separating compounds within a sample so they can be identified and quantified. The method has become one of the most important tools for studying natural and man-made compounds; it is capable of analyzing 80 percent of all compounds. Liquid chromatography has found increasing application in advanced life sciences research due to its ability to analyze large, fragile biomolecules such as proteins.

As a leader in liquid chromatography for three decades, Agilent has played an important role in the evolution of this technology and its applications. The company has led in the development and commercialization of many important LC innovations, such as narrow-bore and ultra-fast separation technology; flow-sensor controlled capillary and nanoflow LC; diode array detection; and sensitive and reliable mass spectrometry. These innovations have enhanced existing applications and enabled new analytical possibilities.

The Agilent 1100 Series has been developed as a scalable, open platform with the flexibility to adapt to novel technologies and evolving user needs. The platform can be configured for a variety of applications, from cutting-edge proteomics research to QA/QC work and from measuring attomoles of peptides to purifying grams of sample. Agilent has developed several application-specific solutions based on the 1100 Series platform:

The Agilent 1100 Series also seamlessly combines with Agilent’s single quadrupole, ion trap and time-of-flight mass spectrometers to provide powerful, fully-integrated MS and MSn systems.

The Agilent 1100 Series LC system can be controlled either via a handheld controller or through a Microsoft(r) Windows(r)-based data system running on a single PC or within a network. Agilent’s networked data systems (NDS) include the Agilent ChemStation and Cerity NDS families, which provide users with advanced instrument control, data acquisition and data management capabilities.

More information about the Agilent 1100 Series LC system is available at www.agilent.com/chem/lc.


About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global technology leader in communications, electronics, life sciences and chemical analysis. The company’s 28,000 employees serve customers in more than 110 countries. Agilent had net revenue of $6.1 billion in fiscal year 2003. Information about Agilent is available on the Web at www.agilent.com.

# # #

Microsoft and Windows are U.S. registered trademarks of Microsoft Corporation.

Contact:

Christina Maehr
+1 408 553 7205
christina_maehr@agilent.com